Abstract:Background: Health insurance is a critical determinant of healthcare access and outcomes in gastrointestinal (GI) cancers. Epidemiological data have shown that insurance-associated healthcare outcomes vary by diagnosis, geographic location, and demographics. Thus, it is critical for cancer providers to understand local impacts of insurance status on patient outcomes. Here, we present real-world outcomes for pancreatic, hepatobiliary, and colorectal cancer (CRC) patients in 11 Midwest hospitals based on insurance status. Methods: We identified patients diagnosed with colorectal, pancreatic, and hepatobiliary cancers within 11 Midwest hospitals from 2011-2021 with North American Association of Central Cancer Registries data. Health insurance was defined as private, Medicaid, Medicare, and uninsured. Effect of insurance status at diagnosis on overall survival (OS) in selected cancers combined and by cancer type were calculated using a Cox proportional hazard (CoxPH) model controlling for age, sex, race, stage, time to treatment initiation (TTI), and Charlson Comorbidity Index (CCI). We evaluated differences in TTI by insurance status using t-tests. We analyzed stage and treatment modality by insurance status using chi-square tests. Post-hoc analysis of TTI by OS used CoxPH. Results: Relative to private insurance, Medicaid and Medicare insurance status significantly reduced OS for all selected GI cancers combined (HR 1.38, 95% CI 1.17 - 1.62 and HR 1.25, 95% CI 1.11 - 1.40, respectively; p<0.001) and for CRC (HR 1.49, 95% CI 1.12 - 1.98 and HR 1.28, 95% CI 1.06 - 1.54, respectively; p<0.01). Uninsured patients had significantly reduced OS only for pancreas cancer (HR 6.36, 95% CI 2.56 - 15.8; p<0.001). No significant associations between insurance status and OS were noted in Hepatobiliary cancer. TTI was significantly associated with insurance status (p<0.001) and mean TTI for Medicaid (35.8 days) and Medicare (27.9 days) patients was longer than mean TTI for privately insured patients (23.3 days; p<0.01). TTI for uninsured patients was not significantly different than for privately insured. Analysis of TTI and OS showed no increased hazard for patients with TTI of 36 days versus 23 days (HR 0.87, 95% CI 0.75 - 1.02; p=0.085). Treatment modality and stage did not differ as a function of insurance status in this dataset. Discussion: Our results expand previous work by demonstrating a survival impact for GI cancer patients with Medicaid or Medicare insurance. This disparity persists despite controlling for known prognostic factors such as age, stage, CCI, and TTI. Notably, TTI varied by insurance suggesting it may account for a portion of this disparity but did not independently drive survival. Further work is required to identify and develop targeted interventions to address other drivers of reduced survival in those without private insurance. Citation Format: Rebecca AbuAyed, Joshua Schwanke, Brooke Patterson, McKenzie White, Schelomo Marmor, Eric Jensen, Christopher Tignanelli, Emil Lou, Ajay Prakash. Real-world analysis of insurance status and survival in patients with selected GI cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6470.

Insurance Denials and Patient Treatment in a Large Academic Radiation Oncology Center

Insurance Denial of Care for Randomized Controlled Trial-Eligible Patients: Incidence and Success Rate of Peer-To-Peer Authorization in Allowing Patients to Remain Trial-Eligible

Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans

Patient Safety and Satisfaction With Fully Remote Management of Radiation Oncology Care

Supplementary Table S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments

An assessment of the association between patient race and prior authorization program determinations in the context of radiation therapy

How automated insurance authorization affects transparency, provider burden, and payer policies and processes: The true impact of prior authorization.

Disparities in access to antineoplastic immunotherapy and outcomes by insurance status: A nationwide analysis.

Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities

Overutilization of IMRT/IGRT in treatment of rectal cancer: Cost implications of deviation from evidence-based practices.

OncoFlash – Research Updates in a Flash! (April 2024 Edition)

Implication of dental insurance status on patterns of pre-radiation dental extraction and risk of osteoradionecrosis of the jaw in head-and-neck cancer patients

The impact of socioeconomic status on overall survival in patients at a radiation oncology center: A retrospective study.

Insurance remains a major source of disparity for patients with testicular cancer: call for advocacy

Socioeconomic and Racial Determinants of Brachytherapy Utilization for Cervical Cancer: Concerns for Widening Disparities

End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting

Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas.

Abstract 6470: Real-world analysis of insurance status and survival in patients with selected GI cancers

Implementation and Efficacy of a Large-Scale Radiation Oncology Case-Based Peer-Review Quality Program across a Multinational Cancer Network

Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy